NO20041732L - Anvendelse av irbesartan for fremstilling av medikamenter som anvendes for a forhindre eller behandle pulmonal hypertensjon - Google Patents

Anvendelse av irbesartan for fremstilling av medikamenter som anvendes for a forhindre eller behandle pulmonal hypertensjon

Info

Publication number
NO20041732L
NO20041732L NO20041732A NO20041732A NO20041732L NO 20041732 L NO20041732 L NO 20041732L NO 20041732 A NO20041732 A NO 20041732A NO 20041732 A NO20041732 A NO 20041732A NO 20041732 L NO20041732 L NO 20041732L
Authority
NO
Norway
Prior art keywords
irbesartan
manufacture
prevent
pulmonary hypertension
treat pulmonary
Prior art date
Application number
NO20041732A
Other languages
English (en)
Other versions
NO332313B1 (no
Inventor
Dino Nisato
Sylvie Cosnier-Pucheu
Alain Roccon
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20041732L publication Critical patent/NO20041732L/no
Publication of NO332313B1 publication Critical patent/NO332313B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
NO20041732A 2001-10-26 2004-04-23 Anvendelse av irbesartan for fremstilling av medisinske produkter som er anvendbare for a forebygge eller behandle pulmonal arteriell hypertensjon eller pulmonal hypertensjon NO332313B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0113936A FR2831446B1 (fr) 2001-10-26 2001-10-26 Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire
PCT/FR2002/003439 WO2003035062A1 (fr) 2001-10-26 2002-10-09 Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire

Publications (2)

Publication Number Publication Date
NO20041732L true NO20041732L (no) 2004-07-23
NO332313B1 NO332313B1 (no) 2012-08-27

Family

ID=8868812

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041732A NO332313B1 (no) 2001-10-26 2004-04-23 Anvendelse av irbesartan for fremstilling av medisinske produkter som er anvendbare for a forebygge eller behandle pulmonal arteriell hypertensjon eller pulmonal hypertensjon

Country Status (24)

Country Link
US (2) US20040242567A1 (no)
EP (1) EP1441723B1 (no)
JP (1) JP4542777B2 (no)
CN (1) CN100418526C (no)
AT (1) ATE361071T1 (no)
AU (1) AU2002350832B2 (no)
BR (1) BR0213479A (no)
CA (1) CA2461625C (no)
CY (1) CY1106746T1 (no)
DE (1) DE60219940T2 (no)
DK (1) DK1441723T3 (no)
EA (1) EA007952B1 (no)
ES (1) ES2286304T3 (no)
FR (1) FR2831446B1 (no)
HU (1) HUP0401633A3 (no)
IL (2) IL161116A0 (no)
IS (1) IS2849B (no)
MX (1) MXPA04003910A (no)
NO (1) NO332313B1 (no)
NZ (1) NZ532130A (no)
PL (1) PL209263B1 (no)
PT (1) PT1441723E (no)
WO (1) WO2003035062A1 (no)
ZA (1) ZA200402696B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
TR200301553A1 (tr) * 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
WO2006067601A1 (en) * 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of irbesartan and hydrochlorothiazide and processes for their preparation
CN100367959C (zh) * 2006-08-29 2008-02-13 陈俊云 一种含有依贝沙坦的药物
GB0617171D0 (en) * 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
AU2022244585A1 (en) * 2021-03-23 2023-09-21 Dimerix Bioscience Pty Ltd Treatment of inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
PT97078B (pt) * 1990-03-20 1997-07-31 Sanofi Sa Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5292741A (en) * 1992-08-18 1994-03-08 Merck & Co., Inc. Macrocycles incorporating quinazolinones
US20020068740A1 (en) 1999-12-07 2002-06-06 Mylari Banavara L. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications

Also Published As

Publication number Publication date
ES2286304T3 (es) 2007-12-01
FR2831446A1 (fr) 2003-05-02
NO332313B1 (no) 2012-08-27
MXPA04003910A (es) 2004-07-23
CY1106746T1 (el) 2012-05-23
HUP0401633A2 (hu) 2004-12-28
PL209263B1 (pl) 2011-08-31
IL161116A0 (en) 2004-08-31
DE60219940D1 (de) 2007-06-14
ATE361071T1 (de) 2007-05-15
IS7200A (is) 2004-03-29
CA2461625A1 (en) 2003-05-01
FR2831446B1 (fr) 2004-03-05
WO2003035062A1 (fr) 2003-05-01
US20040242567A1 (en) 2004-12-02
HUP0401633A3 (en) 2009-06-29
CN1610548A (zh) 2005-04-27
EP1441723A1 (fr) 2004-08-04
IS2849B (is) 2013-09-15
EP1441723B1 (fr) 2007-05-02
AU2002350832B2 (en) 2006-11-30
DE60219940T2 (de) 2008-01-17
NZ532130A (en) 2006-10-27
IL161116A (en) 2010-12-30
JP2005506369A (ja) 2005-03-03
DK1441723T3 (da) 2007-09-10
EA200400438A1 (ru) 2004-10-28
CA2461625C (en) 2011-07-05
CN100418526C (zh) 2008-09-17
JP4542777B2 (ja) 2010-09-15
US20090247510A1 (en) 2009-10-01
BR0213479A (pt) 2004-11-03
PT1441723E (pt) 2007-07-26
US8088827B2 (en) 2012-01-03
PL368737A1 (en) 2005-04-04
EA007952B1 (ru) 2007-02-27
ZA200402696B (en) 2005-06-29

Similar Documents

Publication Publication Date Title
NL300933I2 (nl) Letermovir
NO20052626D0 (no) Middel for forhindring eller behandling av neuropati
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
CY1113105T1 (el) Παραγωγα ξανθινης, η παραγωγη αυτων και η χρηση αυτων ως φαρμακευτικα μεσα
HUP0303363A2 (hu) Kináz-inhibitor hatású heterociklusos vegyületek alkalmazása gyógyszerkészítmények előállítására
NO20071343L (no) Substituerte fenylaminotiazoler og anvendelse derav
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
NO20062561L (no) Kinoliner nyttige for behandling av kardiovaskulaere sykdommer
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
NO20061743L (no) Kinazolinderivater
ATE408601T1 (de) Fredericamycin-derivate
DE60132851D1 (de) Arzneimittel zur Vorbeugung, Erleichterung oder Behandlung von Hypertension
DK1456212T3 (da) 6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse
NO20041732L (no) Anvendelse av irbesartan for fremstilling av medikamenter som anvendes for a forhindre eller behandle pulmonal hypertensjon
DK1246808T3 (da) 1,2-diarylbenzimidazoler til behandling af sygdomme, som er associeret med en mikroglia-aktivering
WO2002010152A3 (de) Neue indolderivate und deren verwendung als arzneimittel
CY1109950T1 (el) Νεα παραγωγα 4,4-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικων) και συνθεσεις που τα περιεχουν
NO20076405L (no) Anvendelse av 24-nor-UDCA
NO20033318D0 (no) 2H-1-benzopyranderivater, fremgangsmåte ved fremstilling samt farmasöytiskesammensetninger derav
AU2002350832A1 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
NO20014081L (no) Anvendelse av tianeptin i produksjonen av medikamenter til behandling av nevrodegenerative patologier
DE60023154D1 (de) Alkoxy-substituierte benzimidazolverbindungen , diese enthaltende arzneimittel und ihre verwendung
CY1110737T1 (el) Υποκατεστημενες ενωσεις 1,5-διαμινοπενταν-3-ολης
DK1425007T3 (da) Anvendelse af C2-substituerede indan-1-ol-systemer til fremstilling af medikamenter til profylaxe eller behandling af obesitas
NO20034998D0 (no) Citalopram til behandling av forhöyet blodtrykk

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees